SCHEMBL9874401

SCHEMBL9874401

Cc1nc2c(Oc3ccccc3)nnc(O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 6/20 0.36
AGTR2 P50052 5/20 0.36
ABCB11 O95342 1/20 0.34
EGFR P00533 1/20 0.34
ERBB2 P04626 1/20 0.34
CYP3A4 P08684 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
CYP2C9 P11712 1/20 0.34
ADRB3 P13945 1/20 0.34
ADRA2B P18089 1/20 0.34
SLC6A2 P23975 1/20 0.34
TBXAS1 P24557 1/20 0.34
HTR2C P28335 1/20 0.34
PPARG P37231 1/20 0.34
HTR2B P41595 1/20 0.34
PDE3A Q14432 1/20 0.34
LTB4R2 Q9NPC1 1/20 0.34
PDE10A Q9Y233 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9873336 0.93 AGTR1 (0.38) AGTR1AGTR2ABCB11EGFRERBB2
SCHEMBL9873634 0.91 AGTR1 (0.37) AGTR1AGTR2PDE10A
SCHEMBL9874579 0.90 AGTR1 (0.35) AGTR1AGTR2ABCB11EGFRERBB2
SCHEMBL9873895 0.89 AGTR1 (0.40) AGTR1AGTR2PDE10A
SCHEMBL9873318 0.89 PPARG (0.33) AGTR1AGTR2ABCB11EGFRERBB2
SCHEMBL9871582 0.89 AGTR1 (0.35) AGTR1AGTR2PPARGPDE10A
SCHEMBL9871494 0.88 PDE10A (0.36) AGTR1AGTR2ABCB11EGFRERBB2
SCHEMBL9872857 0.88 AGTR1 (0.36) AGTR1AGTR2ABCB11EGFRERBB2
SCHEMBL9874147 0.88 AGTR1 (0.34) AGTR1AGTR2
SCHEMBL9872981 0.88 AGTR1 (0.38) AGTR1AGTR2ABCB11EGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1991019715-A1 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1991-12-26 WO disclosed